Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(2):91-93; doi:10.1093/jnci/95.2.91
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vogel, V. G.
Right arrow Articles by Lo, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogel, V. G.
Right arrow Articles by Lo, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 2, 91-93, January 15, 2003
© 2003 Oxford University Press

EDITORIAL

Preventing Hormone-Dependent Breast Cancer in High-Risk Women

Victor G. Vogel, Shelly Lo

Affiliations of authors: V. G. Vogel, S. Lo, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Correspondence to: Victor G. Vogel, M.D., M.H.S., Magee/UPCI Breast Program, University of Pittsburgh School of Medicine, 300 Halket St., Rm. 3524, Pittsburgh, PA 15213–3180 (e-mail: vvogel@mail.magee.edu).

The first 150 words of the full text of this article appear below.

Chemoprevention is the use of specific natural or synthetic chemical agents to reverse, suppress, or prevent the progression of premalignant lesions to invasive carcinoma. Four major trials have used tamoxifen, the prototypical selective estrogen receptor modulator (SERM), as a breast cancer chemopreventive agent with differing results. The Royal Marsden trial (1), a pilot study for the International Breast Cancer Intervention Study (IBIS-I) trial (2), and the initial analysis of the Italian tamoxifen prevention study (3) showed no decrease in the incidence of breast cancer among women using tamoxifen. By contrast, both the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 study (4) and the IBIS-I trial (2) did show reduction in breast cancer risk with tamoxifen.

In this issue of the Journal, the authors of the Italian study have re-analyzed their data after a median follow-up of 81.2 months . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
U. Veronesi, P. Maisonneuve, N. Rotmensz, B. Bonanni, P. Boyle, G. Viale, A. Costa, V. Sacchini, R. Travaglini, G. D'Aiuto, et al.
Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy
J Natl Cancer Inst, May 2, 2007; 99(9): 727 - 737.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J G Moggs, T C Murphy, F L Lim, D J Moore, R Stuckey, K Antrobus, I Kimber, and G Orphanides
Anti-proliferative effect of estrogen in breast cancer cells that re-express ER{alpha} is mediated by aberrant regulation of cell cycle genes
J. Mol. Endocrinol., April 1, 2005; 34(2): 535 - 551.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. E. Curtis, D. M. Freedman, M. E. Sherman, and J. F. Fraumeni Jr.
Risk of Malignant Mixed Mullerian Tumors After Tamoxifen Therapy for Breast Cancer
J Natl Cancer Inst, January 7, 2004; 96(1): 70 - 74.
[Abstract] [Full Text] [PDF]